Business context and reporting period
China Pharma Holdings, Inc. filed this Form 10-K for the fiscal year ended December 31, 2014; it reports full-year results, not standalone fourth-quarter results. The company develops, manufactures and sells prescription pharmaceuticals in China, primarily through its PRC subsidiary, Helpson.
During 2014, the company completed a new factory and received CFDA GMP certification in November, allowing two liquid-injectable and two dry-powder-injectable lines to begin operating in the fourth quarter. The old injectable lines had been suspended from January 1 through November 3 for failure to meet the GMP upgrade deadline.
Financial results and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $24.9 million | $32.8 million |
| Gross profit (loss) | $5.5 million | $(0.5) million |
| Gross margin | 22.0% | (1.5)% |
| Operating loss | $(25.3) million | $(18.6) million |
| Net loss | $(26.0) million | $(20.0) million |
| Loss per share | $(0.60) | $(0.46) |
| Cash from operations | $4.6 million | $8.6 million |
| Cash used in investing | $(5.8) million | $(19.1) million |
Revenue fell 24%. Sales declined across all reported product categories: CNS/cerebral/cardiovascular 39%, anti-infective/respiratory 10%, digestive 55%, and other 37%. Cost of revenue was $17.2 million. Inventory obsolescence expense was $2.3 million, versus $9.9 million in 2013; management estimates gross margin excluding this expense at 30.9% and 28.7%, respectively.
Bad-debt expense rose to $20.6 million from $10.8 million. Net trade receivables were $24.9 million, with a $33.4 million doubtful-account allowance; $23.6 million of receivables were past due. Inventory was $15.3 million, down from $24.7 million.
Year-end cash was $5.3 million, down from $6.0 million; management stated that the cash was held in Helpson and not expected to be available for parent-company payments or dividends. Total assets were $132.1 million and total liabilities were $25.8 million. Debt included $4.9 million of short-term notes payable, due November 2015, and a construction loan facility with approximately $13.0 million outstanding. The construction loan is secured by the new facility and equipment; principal installments began in July 2015. A director-related loan of $1.35 million was also outstanding.
Changes, outlook and material matters
- Management attributed weaker results to the injectable-line suspension, lower sales, tighter credit sales and collections, and heightened bad-debt charges. The typhoon Rammasun caused approximately $2.28 million of losses in July 2014, mainly inventory and facility damage.
- Management expected operating cash to cover working capital and anticipated capital spending for the next 12 months, but said additional financing might be needed if plans or conditions changed. No specific revenue or earnings guidance was provided.
- Pipeline candidates included rosuvastatin, awaiting production approval after supplemental work; a combination antibiotic in Phase II; and a coronary heart disease product approaching the end of Phase III. The filing cautions that CFDA review delays and approvals are uncertain.
- Pricing, reimbursement, tendering and regulatory changes in China may pressure sales and margins. The company also faces distributor and customer concentration, slow collections, supplier concentration, competition, foreign-exchange and cash-remittance restrictions, and dependence on a single PRC manufacturing base. One distributor accounted for 16.2% of 2014 revenue; the five largest accounted for 31%.
- The company reported ineffective internal control over financial reporting at year-end, citing material weaknesses in inventory-obsolescence and property-and-equipment accounting and insufficient U.S. GAAP expertise. Management described training and education as remediation steps. The auditor gave an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
- The filing’s MD&A describes 2014 income tax expense as approximately $0.8 million, while the audited statement and tax note report $77,042. The filing text does not provide a clear reconciliation.
Important facts for investors to verify
- Collectability and aging of receivables, adequacy of the $33.4 million allowance, and whether collections improved after year-end.
- Whether the newly certified injectable lines operated at expected capacity and whether the remaining facility upgrades received required GMP approvals.
- Debt repayment capacity, the start and schedule of construction-loan principal payments, and access to cash restricted within China.
- Progress and CFDA approval status of pipeline products, especially rosuvastatin and the Phase II combination antibiotic.
- Remediation of the internal-control material weakness and reconciliation of the income-tax figures disclosed in MD&A versus the audited statements.